Last reviewed · How we verify
NCT05168722
COVID-19, Patients' Evolution and the Influence of the Pandemic on Health Care and Outcomes in Chronic Diseases
trial testing No interventions in COVID-19 Pandemic in 2,220 participants. Completed in 31 January 2025.
31 December 2024
Quick facts
| Lead sponsor | Hospital Galdakao-Usansolo |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,220 |
| Start date | 28 February 2022 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 January 2025 |
| Sites | 5 locations across Spain |
Drugs / interventions tested
- No interventions — full drug profile →
Conditions studied
- COVID-19 Pandemic — all drugs for COVID-19 Pandemic →
- Pulmonary Disease, Chronic Obstructive — all drugs for Pulmonary Disease, Chronic Obstructive →
- Heart Failure, Congestive — all drugs for Heart Failure, Congestive →
- Depressive Symptoms — all drugs for Depressive Symptoms →
Sponsor
Hospital Galdakao-Usansolo
Who can join
18 and older, any sex, with COVID-19 Pandemic or Pulmonary Disease, Chronic Obstructive. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Objectives: 1.- To evaluate the changes in health care and use of services in patients with chronic diseases such as chronic obstructive pulmonary disease (COPD), heart failure and major depression between 2017-2019 and the years 2020-2022, COVID pandemic period, and to see their relationship with clinical outcomes (in terms of mortality, admissions, death, current situation of his disease) and changes in health-related quality of life. 2- To evaluate the health care provided to a cohort of patients diagnosed with SARSCOV-2 (COVID-19 positive) during 2020 based on accessibility, equity and outcomes obtained. 3-To evaluate the evolution of the cohort of patients diagnosed with SARSCOV-2 after two years of follow-up since their diagnosis and create clinical prediction rules for the persistence of symptoms. Methodology. Four cohorts already created in previous projects are included: three of chronic patients, COPD, heart failure, major depression, all of 2017, and for which baseline information is available for follow-up of the health care they received in the 2017-19 period compared to that received during the 2020-22 period and to see the changes in their health-related quality of life from baseline based on generic and specific questionnaires for each of the pathologies included. Another cohort of positive and admitted patients for COVID-19 in 2020 is included, in whom the services received will be evaluated and recorded symptoms persistency that may have had up to two years after their index admission to develop tools for predicting the persistence of symptoms in the medium-long term.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05168722
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No interventions
Trials testing the same drug.
- NCT07497815 — Artificial Intelligence-assisted Diagnosis in Ophthalmology · not yet recruiting
- NCT07509632 — Predicting Pathological Complete Response in Rectal Cancer Using Machine Learning · active not recruiting
- NCT07307040 — Precision Diabetes Management: Integrated East-West Approach · not yet recruiting
- NCT07276945 — Individualized Early Diagnosis and Treatment System of Gestational Diabetes Mellitus (GDM) Based on New Continuous Gluco · not yet recruiting
- NCT06999681 — Postoperative Arrhythmia and Preoperative Cardiac Function · not yet recruiting
Other recruiting trials for COVID-19 Pandemic
Currently open trials in the same condition.
- NCT05825651 — Long COVID and Its Associations With Health Outcomes in Older Adults · active not recruiting
- NCT06927622 — Corona Virus Disease 2019 Cohort Study · recruiting
- NCT05096260 — Getting to Yes, Michigan! (G2YMI) · NA · active not recruiting
- NCT06208943 — Neural and Cognitive Consequences of COVID-19 Survival · recruiting
Other Hospital Galdakao-Usansolo trials
Trials by the same sponsor.
- NCT07401407 — RICA (ERAS) Pathway Adherence and Early Discharge Feasibility After Urgent Uncomplicated Appendectomy (APENERAS) · completed
- NCT05574790 — Identification of Multimorbid Patients With a Higher Probability of Readmission and Mortality · completed
- NCT04188990 — Cost Effectiveness of an Intervention in Hospitalized Patients With Disease-related Malnutrition · NA · completed
- NCT04463706 — COVID19 Severity Prediction and Health Services Research Evaluation · completed
- NCT05247307 — Efficacy of the Infusion of Donor Plasma in COVID-19 Infection · Phase 3 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05168722 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Galdakao-Usansolo
- Last refreshed: 13 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05168722.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing